Adagene (ADAG) Current Deferred Revenue (2019 - 2026)
Adagene (ADAG) posted quarterly Current Deferred Revenue of $3462.7 billion for Q4 2025, up 325.96% quarter-over-quarter from $812.9 billion in Q2 2023.
Analysis
Adagene (ADAG) Current Deferred Revenue (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Current Deferred Revenue for 6 consecutive years, with $3462.7 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue changed N/A year-over-year to $3462.7 billion; the TTM figure through Dec 2025 stood at $3462.7 billion (changed N/A YoY), while the FY2025 annual figure was $3462.7 billion, changed N/A from the prior year.
- Current Deferred Revenue climbed to $3462.7 billion in Q4 2025 per ADAG's latest filing, from $812.9 billion in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $20176.8 billion in Q2 2022 and bottomed at $5.5 million in Q4 2021.
- Historically, Current Deferred Revenue has averaged $6593.3 billion across 4 years, with a median of $2137.8 billion in 2023.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 274677645.45% — and 2023, when it slumped 95.97%.
- Adagene's Current Deferred Revenue stood at $5.5 million in 2021, then soared by 274677645.45% to $15107.3 billion in 2022, then tumbled by 94.62% to $812.9 billion in 2023, then soared by 325.96% to $3462.7 billion in 2025.
- Business Quant data shows ADAG's Current Deferred Revenue at $3462.7 billion in Q4 2025, $812.9 billion in Q2 2023, and $15107.3 billion in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Adagene | 211.24 Mn | 211.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.18 Mn |
| Dec 31, 2025 | 3.46 Mn |
| Jun 30, 2023 | 812,916.00 |
| Dec 31, 2022 | 15.11 Mn |
| Jun 30, 2022 | 20.18 Mn |
| Dec 31, 2021 | 5.50 Mn |
| Jun 30, 2021 | 11.10 Mn |
| Dec 31, 2020 | 725,536.00 |
| Dec 31, 2019 | 993,378.00 |